{
  "meta": {
    "data_length": 1,
    "message": "Document id doc:hc.retevmo retrieved successfully",
    "request_url": "http://api.moalmanac.org/documents?document_id=doc%3Ahc.retevmo",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.003186,
    "timestamp_received": "2026-04-06T14:30:29.297598+00:00Z",
    "timestamp_returned": "2026-04-06T14:30:29.300784+00:00Z",
    "trace_id": "176b2b9f-36de-43ad-bb86-880f47d346a9"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://dev.moalmanac.org",
    "last_updated": "2026-03-05"
  },
  "data": [
    {
      "id": "doc:hc.retevmo",
      "type": "Document",
      "documentType": "Regulatory approval",
      "name": "Retevmo (selpercatinib) [product monograph]. HC.",
      "title": null,
      "aliases": [],
      "description": "Loxo Oncology Inc. Retevmo (selpercatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078253.PDF. Revised January 2025. Accessed June 2025.",
      "urls": [
        "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100625",
        "https://pdf.hres.ca/dpd_pm/00078253.PDF"
      ],
      "doi": null,
      "pmid": null,
      "extensions": [
        {
          "name": "agent",
          "value": {
            "id": "hc",
            "type": "Agent",
            "agentType": "organization",
            "name": "Health Canada",
            "description": "Regulatory agency that approves drugs for sale and use in Canada.",
            "extensions": [
              {
                "name": "last_updated",
                "value": "2025-06-11",
                "description": ""
              },
              {
                "name": "url",
                "value": "https://health-products.canada.ca/dpd-bdpp/",
                "description": ""
              }
            ]
          },
          "description": "The organization that published this document."
        },
        {
          "name": "company",
          "value": "Loxo Oncology Inc.",
          "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
        },
        {
          "name": "drug_name_brand",
          "value": "Retevmo",
          "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
        },
        {
          "name": "drug_name_generic",
          "value": "selpercatinib",
          "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
        },
        {
          "name": "first_publication_date",
          "value": "2021-06-11",
          "description": "The publication date for the initial version of this document."
        },
        {
          "name": "identification_number",
          "value": null,
          "description": "Identification number used by the publishing organization."
        },
        {
          "name": "publication_date",
          "value": "2025-01-10",
          "description": "The publication date for the document."
        },
        {
          "name": "status",
          "value": "Active",
          "description": "Whether this document is Active or Deprecated within moalmanac-db."
        }
      ]
    }
  ]
}